OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab
Zequn Tong, Yihua Zhang, Kunli Zhou, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 4, pp. 826-828
Closed Access | Times Cited: 6
Zequn Tong, Yihua Zhang, Kunli Zhou, et al.
Journal of the American Academy of Dermatology (2023) Vol. 89, Iss. 4, pp. 826-828
Closed Access | Times Cited: 6
Showing 6 citing articles:
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry
Esmé Kamphuis, Celeste M. Boesjes, Laura Loman, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv19454-adv19454
Open Access | Times Cited: 13
Esmé Kamphuis, Celeste M. Boesjes, Laura Loman, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv19454-adv19454
Open Access | Times Cited: 13
Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24‐week multicenter study
José Carlos Armario Hita, J Rodríguez, Alicia González‐Quesada, et al.
International Journal of Dermatology (2024) Vol. 63, Iss. 11
Open Access | Times Cited: 4
José Carlos Armario Hita, J Rodríguez, Alicia González‐Quesada, et al.
International Journal of Dermatology (2024) Vol. 63, Iss. 11
Open Access | Times Cited: 4
Abrocitinib Treatment Modes: Impact on Prognosis and Relapse Rates in Atopic Dermatitis
Sisi Deng, Jiong Fu, Xueqin Chen, et al.
Dermatitis (2025)
Closed Access
Sisi Deng, Jiong Fu, Xueqin Chen, et al.
Dermatitis (2025)
Closed Access
Effectiveness and safety of age-based dosing of abrocitinib in children and adolescents with moderate to severe atopic dermatitis: A two-center, prospective real-world study in China
Jingyao Liang, Hui Ye, Jun Wang, et al.
Medicine (2025) Vol. 104, Iss. 16, pp. e42231-e42231
Open Access
Jingyao Liang, Hui Ye, Jun Wang, et al.
Medicine (2025) Vol. 104, Iss. 16, pp. e42231-e42231
Open Access
Dupilumab in Combination With JAK Inhibitor for Refractory Moderate‐to‐Severe Atopic Dermatitis
Xiaoting Song, Bo Liu, Chengyue Peng, et al.
Dermatologic Therapy (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 1
Xiaoting Song, Bo Liu, Chengyue Peng, et al.
Dermatologic Therapy (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 1
Effects of abrocitinib on pruritus and eczema symptoms and tolerance in patients with moderate‑to‑severe atopic dermatitis in randomized, double‑blind and placebo‑controlled trials: A systematic review and a meta‑analysis
Xingxing Xie, Jie Zhang, Fujing Huang, et al.
Biomedical Reports (2024) Vol. 20, Iss. 5
Open Access
Xingxing Xie, Jie Zhang, Fujing Huang, et al.
Biomedical Reports (2024) Vol. 20, Iss. 5
Open Access
Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study
Samantha Keow, Mohannad Abu‐Hilal
Journal of the American Academy of Dermatology (2024)
Open Access
Samantha Keow, Mohannad Abu‐Hilal
Journal of the American Academy of Dermatology (2024)
Open Access
